J+D helps pioneering biotech launch an efficient, best-practice forecasting process
The adoption of Onco+ has helped this biotech cut the forecast development pipeline significantly and supported best practice forecasting within their team.
A clinical-stage biotech, with a broad oncology pipeline required an improved forecasting approach to support their launch strategy and pipeline prioritisation decision-making for a novel and innovative oncology technology.
Their lead asset was in Phase III development, and they urgently needed to establish a more robust forecasting approach to support its commercialisation.
The recently hired CCO had worked with J+D Forecasting for several years at his previous company and was looking for help implementing the necessary infrastructure to support the company’s short and medium-term challenges.
With over a decade of global forecasting experience and their patented FC+ pharma forecasting software, J+D were ideally positioned to resolve these challenges.
The FC+ software was an ideal solution as it delivered best practice forecasting that was efficient and supported better transparency and consistency for the team. Also, by selecting the oncology specific option, Onco+, they could use the built-in patient flow methodology. Meaning, the complex algorithms necessary for robust oncology forecasting would be ready for them to use out of the box.
By combining this with access to our forecasting experts for consultancy and training, the client would be able to meet both their short-term and longer-term needs.
The first step was to run a complete data and methodology audit together with an in-depth discussion to understand the company’s needs.
This resulted in the following steps:
The clinical-stage biotech accomplished the short-term goal of having a more robust and accurate forecast for their lead asset. Working closely with J+D’s forecasting experts, the client created the model quickly, using Onco+ software, and ran a detailed data and assumptions audit.
The objective of upskilling the internal team was met through coaching and training, using case examples. The team is now fully independent in the development of sophisticated oncology models. The client is now confident in generating and communicating forecasts that identify their pipeline assets’ commercial opportunities and risks.
Finally, by using Onco+ software, there is now an efficient forecasting process that is both time and cost-efficient, allowing for scenario analysis, country and regional deployment with automated consolidation and reporting. All models are built using best practice forecasting principles and are easy to update, amend and share across the stakeholder team.